TNXP · Tonix Pharmaceuticals Holding Corp.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Equibles Research
All TNXP researchTechnicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| prescriptions filled for TONMYA | 5,400 | Q1 2026 | — |
| prescriptions filled for TONMYA (cumulative) | 11,016 | November 17, 2025 through May 1, 2026 | — |
| unique healthcare providers prescribed TONMYA | 2,145 | Q1 2026 | — |
| unique healthcare providers prescribed TONMYA (cumulative) | 2,700 | November 17, 2025 through April 24, 2026 | — |
| unique patients initiated treatment with TONMYA | 3,588 | Q1 2026 | — |
| unique patients initiated treatment with TONMYA (cumulative) | 5,618 | November 17, 2025 through April 24, 2026 | — |
| cumulative prescriptions for TONMYA | 4,200 | November 17, 2025–February 27, 2026 (launch-to-date) | — |
| healthcare providers who have prescribed TONMYA | 1,500 | November 17, 2025–February 27, 2026 (launch-to-date) | — |
| patients who have initiated treatment with TONMYA | 2,500 | November 17, 2025–February 27, 2026 (launch-to-date) | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNXP
this stock
Tonix Pharmaceuticals Holding Corp.
|
$198.14M | -20.4% | +29.8% | — | 22.5% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNXP | -0.8% | +1.9% | -32.2% | -2.6% | -20.4% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | +0.7% | +1.6% | -40.0% | -2.1% | -29.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.